Program
Tenofovir
Also written as “Tenofovir disoproxil fumarate”, “Tenofovir DF” and “tenofovir”.
Its studies are mostly in Hepatitis B, Chronic · HIV Infections · Hepatitis B · Acquired Immunodeficiency Syndrome · Hepatitis C, led by 12 companies.
Drug pageTenofovir: every studyMany companies study it; this page follows only the 53 they lead. All 291 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciencesits history only | 291 open or running | phase 4since Mar 23, 2005 | Nov 2, 1999 | none ahead |
| GlaxoSmithKlineits history only | 90 open or running | phase 4since May 31, 2002 | May 31, 2002 | none ahead |
| Hoffmann-La Rocheits history only | 30 open or running | phase 3since Mar 16, 2010 | Aug 19, 2009 | none ahead |
| Laboratorio Elea Phoenixits history only | 20 open or running | phase 4since Oct 10, 2017 | Oct 19, 2015 | none ahead |
| Novartisits history only | 20 open or running | phase 4since Dec 7, 2006 | Dec 7, 2006 | none ahead |
| Samjin Pharmaceuticalits history only | 20 open or running | phase 4since Feb 25, 2022 | Feb 25, 2022 | none ahead |
| Boryung Pharmaceuticalits history only | 10 open or running | phase 1since Sep 29, 2016 | Sep 29, 2016 | none ahead |
| Daewoong Pharmaceuticalits history only | 10 open or running | phase 4since Mar 27, 2018 | Mar 27, 2018 | none ahead |
| Dong-A STits history only | 10 open or running | phase 1since Sep 22, 2015 | Sep 22, 2015 | none ahead |
| New Discoveryits history only | 10 open or running | phase 4since Mar 18, 2018 | Mar 18, 2018 | none ahead |
| Viatrisits history only | 10 open or running | phase 4since Apr 25, 2022 | Apr 25, 2022 | none ahead |
| Yung Shin Pharm. Ind.its history only | 10 open or running | phase 4since Dec 15, 2020 | Dec 15, 2020 | none ahead |
Also a collaborator on its studies: C&R Research, Almedis and Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 38 studies since Nov 2, 1999.
- Aug 21, 2012Phase 1 study in Hepatitis B, ChronicGilead Sciences · NCT01671787 · 51 enrolled · United States, Australia, Canada and more
- Jul 17, 2014Phase 4 study in Hepatitis B, ChronicGlaxoSmithKline · NCT02195518 · 213 enrolled · China
- Aug 21, 2014Phase 4 study in Hepatitis B, ChronicGlaxoSmithKline · NCT02224456 · 197 enrolled · China
- Jun 17, 2015Phase 4 study in Hepatitis BGilead Sciences · NCT02479880 · 30 enrolled · Belgium, France, Greece and more
- Sep 22, 2015Dong-A ST’s first study: phase 1 study in Hepatitis BNew to Dong-A STDong-A ST · NCT02557594 · 36 enrolled · Korea, Republic of
- Oct 19, 2015Laboratorio Elea Phoenix’s first study: phase 1 study in Acquired Immunodeficiency SyndromeNew to Laboratorio Elea PhoenixLaboratorio Elea Phoenix · NCT02583464 · 24 enrolled · Argentina
- Jun 9, 2016Named tenofovirINNProposed as its International Nonproprietary Name in WHO's List 115
- Sep 29, 2016Boryung Pharmaceutical’s first study: phase 1 study in HepatitisNew to Boryung PharmaceuticalBoryung Pharmaceutical · NCT02920931 · 50 enrolled · Korea, Republic of
- Aug 21, 2017Phase 4 study in Hepatitis B, ChronicGlaxoSmithKline · NCT03258710 · 75 enrolled · Japan
- Oct 10, 2017Phase 4 study in HealthyLaboratorio Elea Phoenix · NCT03309566 · 24 enrolled · Argentina
- Mar 18, 2018New Discovery’s first study: phase 4 study in Hepatitis BNew to New DiscoveryNew Discovery · NCT03476083 · 280 enrolled · China
- Mar 27, 2018Daewoong Pharmaceutical’s first study: phase 4 study in Hepatitis B, ChronicNew to Daewoong PharmaceuticalDaewoong Pharmaceutical · NCT03485534 · 189 enrolled · Korea, Republic of
- Dec 15, 2020Yung Shin Pharm. Ind.’s first study: phase 4 study in Pharmacokinetic of Tenofovir in Healthy SubjectsNew to Yung Shin Pharm. Ind.Yung Shin Pharm. Ind. · NCT04671563 · 28 enrolled · Taiwan
- Feb 25, 2022Samjin Pharmaceutical’s first studies: 2 phase 4 studies in Hepatitis B, ChronicNew to Samjin PharmaceuticalSamjin Pharmaceutical · NCT05286346, NCT05282407
- Apr 25, 2022Viatris’s first study: phase 4 study in Hepatitis B, ChronicNew to ViatrisViatris · NCT05355467 · 40 enrolled · Taiwan
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 53 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05355467Hepatitis B, Chronic · Taiwan | 4 | Completed | Viatris | Jul 13, 2021 | 40 |
| NCT05286346Hepatitis B, Chronic · Korea, Republic of | 4 | Completed | Samjin Pharmaceutical | Aug 10, 2020 | 113 |
| NCT05282407Hepatitis B, Chronic · Korea, Republic of | 4 | Completed | Samjin Pharmaceutical | Apr 17, 2019 | 118 |
| NCT04671563Pharmacokinetic of Tenofovir in Healthy Subjects · Taiwan | 4 | Completed | Yung Shin Pharm. Ind. | May 9, 2020 | 28 |
| NCT03485534Hepatitis B, Chronic · Korea, Republic of | 4 | Completed | Daewoong Pharmaceutical | Nov 4, 2019 | 189 |
| NCT03476083Hepatitis B · China | 4 | UNKNOWN | New Discovery | May 2021 | 280 |
| NCT03309566Healthy · Argentina | 4 | Completed | Laboratorio Elea Phoenix | Feb 28, 2017 | 24 |
| NCT03258710Hepatitis B, Chronic · Japan | 4 | Completed | GlaxoSmithKline | Dec 28, 2018 | 75 |
| NCT02920931Hepatitis · Korea, Republic of | 1 | Completed | Boryung Pharmaceutical | Apr 2016 | 50 |
| NCT02583464Acquired Immunodeficiency Syndrome · Argentina | 1 | Completed | Laboratorio Elea Phoenix | Oct 2014 | 24 |
| NCT02557594Hepatitis B · Korea, Republic of | 1 | Completed | Dong-A ST | Nov 17, 2015 | 36 |
| NCT02479880Hepatitis B · Belgium, France, Greece and more | 4 | Terminated | Gilead Sciences | Feb 28, 2018 | 30 |
| NCT02224456Hepatitis B, Chronic · China | 4 | Completed | GlaxoSmithKline | Dec 4, 2020 | 197 |
| NCT02195518Hepatitis B, Chronic · China | 4 | Completed | GlaxoSmithKline | Aug 14, 2018 | 213 |
| NCT01671787Hepatitis B, Chronic · United States, Australia, Canada and more | 1 | Completed | Gilead Sciences | Apr 2013 | 51 |
| NCT01651403Hepatitis B, Chronic · United States, India, Romania and more | 3 | Active, not recruiting | Gilead Sciences | Aug 7, 2017 | 90 |
| NCT01592305Healthy Volunteer · United States | 1 | Completed | Hoffmann-La Roche | Jun 2012 | 40 |
| NCT01480284Hepatitis B, Chronic · Japan | 3 | Completed | GlaxoSmithKline | Jan 2013 | 166 |
| NCT01480622Hepatitis B, Chronic · China | 1 | Completed | GlaxoSmithKline | Dec 30, 2011 | 14 |
| NCT01475851Hepatitis B, Chronic · Japan | 3 | Completed | GlaxoSmithKline | Jun 2013 | 34 |
| NCT01300234Hepatitis B · China | 3 | Completed | GlaxoSmithKline | Oct 17, 2012 | 512 |
| NCT01277601Hepatitis B, Chronic · United States, Australia, Canada and more | 4 | Completed | Gilead Sciences | Aug 2014 | 751 |
| NCT01334567Hepatitis B · Taiwan | 2 | Completed | Gilead Sciences | Dec 2013 | 30 |
| NCT01088659Hepatitis D, Chronic · Turkey | 3 | Completed | Hoffmann-La Roche | Dec 29, 2017 | 50 |
| NCT00962871Hepatitis B, Chronic · United States, New Zealand, Singapore and more | 1 | Completed | Hoffmann-La Roche | Feb 2012 | 30 |
| NCT00737568Hepatitis B · United States, Austria, Bulgaria and more | 3 | Completed | Gilead Sciences | Nov 2011 | 280 |
| NCT00736190Hepatitis B, Chronic · United States | 4 | Completed | Gilead Sciences | Jul 2010 | 90 |
| NCT00734162Hepatitis B · United States, Bulgaria, France and more | 3 | Completed | Gilead Sciences | Mar 2011 | 106 |
| NCT00648817HIV Infections · United Kingdom | 4 | Completed | Gilead Sciences | Nov 2007 | 8 |
| NCT00647946Lipodystrophy · United Kingdom | 2 | Completed | Gilead Sciences | Oct 2004 | 100 |
| NCT00643968HIV Infections · France | 4 | Completed | Gilead Sciences | Jun 2005 | 140 |
| NCT00651209Hepatitis B, Chronic · Argentina, Brazil, Germany and more | 4 | Completed | Novartis | Dec 2011 | 105 |
| NCT00615745HIV Infections · United Kingdom | 4 | Completed | Gilead Sciences | Nov 2010 | 115 |
| NCT00528957HIV Infections · United States, Panama, United Kingdom | 3 | Completed | Gilead Sciences | Apr 6, 2009 | 97 |
| NCT00409019Hepatitis B, Chronic | 4 | Withdrawn | Novartis | Mar 2011 | 0 |
| NCT00365612HIV Infections · United States, Puerto Rico | 4 | Completed | Gilead Sciences | Oct 2007 | 300 |
| NCT00352053HIV Infections · Brazil, Panama | 3 | Completed | Gilead Sciences | Sep 2008 | 87 |
| NCT00324688HIV Infections · Germany | 4 | Completed | Gilead Sciences | 60 | |
| NCT00307489Hepatitis B, Chronic · United States, France, Germany and more | 2 | Completed | Gilead Sciences | Jan 2008 | 106 |
| NCT00298363Hepatitis B, Chronic · United States, Canada, France and more | 2 | Completed | Gilead Sciences | Apr 2011 | 112 |
| NCT00158821HIV Infections | 3 | Completed | Gilead Sciences | Dec 2001 | 180 |
| NCT00112047HIV Infections · United States | 3 | Completed | Gilead Sciences | Feb 2005 | 517 |
| NCT00106379HIV Infections · United States | 4 | Completed | Gilead Sciences | 52 | |
| NCT00053638HIV Infections · United States | 3 | Completed | GlaxoSmithKline | Oct 2004 | 345 |
| NCT00038506HIV Infections · United States | 4 | Completed | GlaxoSmithKline | Aug 2004 | 100 |
| NCT00016588HIV Infections · United States | – | Completed | Gilead Sciences | ||
| NCT00011089HIV Infections · United States | – | UNKNOWN | Gilead Sciences | ||
| NCT00007436HIV Infections · United States | 3 | UNKNOWN | Gilead Sciences | ||
| NCT00002453HIV Infections · United States | – | Completed | Gilead Sciences | 300 | |
| NCT00002450HIV Infections · United States, Puerto Rico | 3 | Completed | Gilead Sciences | 600 | |
| NCT00002415HIV Infections · United States | 2 | Completed | Gilead Sciences | 175 | |
| NCT00002396HIV Infections · United States | 1 | UNKNOWN | Gilead Sciences | 60 | |
| NCT00002180HIV Infections · United States | 1 | Completed | Gilead Sciences |
How it is read
Names in the registry
- “Tenofovir disoproxil fumarate”, 13 entries
- “Tenofovir”, 7 entries
- “Tenofovir DF”, 6 entries
- “tenofovir”, 5 entries
- “TDF”, 4 entries
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 29 studies
- HIV Infections, 23 studies
- Hepatitis B, 6 studies
- Acquired Immunodeficiency Syndrome, 4 studies
- Hepatitis C, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.